Purpose: Because immune mediated mechanisms are suspected in epileptogenesis, IVIg and corticosteroids have been used as alternatives to treat refractory seizures. We present our experience treating intractable epileptic children with IVIg and prednisone. Methods: Children with intractable epilepsy treated with prednisone or IVIg between 2005-2016 were reviewed retrospectively. Children with infantile spasms and autoimmune epilepsy were excluded. Data analyzed include epilepsy type and etiology, duration of epilepsy prior to treatment, seizure outcome, time to best seizure outcome, and adverse effects. Results: Fifty-one patients were included: 26 received IVIg; 25 received prednisone. Etiologies were similar between cohorts: genetic (13 IVIg; 10 prednisone), lesional (8 IVIg; 7 prednisone), and unknown (5 IVIg; 8 prednisone). In the prednisone cohort, 92.0% had generalized epilepsy compared to 61.5% for IVIg. Among the IVIg treated, 84.6% responded (10 genetic, 4 unknown, and 8 lesional) with mean seizure reduction of 77.3% and mean time to best response of 9.8 weeks. With prednisone, 24.0% responded (2 genetic, 3 unknown, and 1 lesional) with a mean seizure reduction of 95.0% and mean time to best response of 2.7 weeks. Adverse effects occurred in 2 and 16 patients treated with IVIg and prednisone, respectively. The difference in responders and seizure reduction was statistically significant (p < 0.0001 and p = 0.001, respectively). Conclusion: IVIg had greater responders and lower adverse effects and honeymoon effect. This response was independent of epilepsy type, etiology, and duration suggesting different mechanisms of action between prednisone and IVIg and a common, reversible, immune-mediated pathway to intractability.
Introduction
Paediatric intractable epilepsy remains a problematic condition with high morbidity due to the high seizure burden and to the multiple antiepileptic medications (AEDs) used. Because AEDs share similar mechanisms of action aimed at affecting neuronal ion channels or neurotransmitter receptors, it is not surprising that the likelihood of additional AEDs resulting in significant seizure reduction is low. In addition, it is unclear if AEDs can modify the underlying process promoting seizures.
Neuroinflammation has been suspected to play a role in epileptogenesis and in the cycle of events leading to intractability. This notion is supported by animal models and by imaging and pathological studies in patients with intractable epilepsy [1] [2] [3] [4] . With this hypothesis in mind, treatment with high dosage prednisone and intravenous immunoglobulins (IVIg) have been tried with the goal to break the cycle leading to refractory seizures [4] and to employ mechanisms that do not cause or compound the adverse effects of conventional AEDs.
To date, studies examining the use of IVIg and prednisone in epilepsy have been limited due to differences in treatment methodology and patient population [5] [6] [7] [8] . Currently, there is no clear consensus of superiority or inferiority between these two treatment options on seizure control. Furthermore, details on timing of response, duration of effect, relapse rate, and long term outcome are lacking.
In this study, a cohort of children treated with IVIg is compared to a cohort treated with high dosage prednisone. Etiology, outcome, the course of epilepsy during treatment, and adverse effects are among the factors examined.
Materials and methods
Patients were obtained from a pediatric epilepsy clinic (RTW) specializing in intractable pediatric epilepsy and serving northern Alberta, Saskatchewan, Yukon and Northwest Territories, and British Columbia. Patients under age 17 years who failed at least 2 AEDs and were treated with IVIg or prednisone from 2005 to 2016 and were included. Children with a clear or suspected immunological etiology for their epilepsy (e.g., Rasmussen's Encephalitis) or with infantile spasms and hypsarrhythmia were excluded. Children with a prior history of infantile spasms were included if they had a different type of epilepsy without hypsarrhythmia at the time of prednisone or IVIg. Of note, IVIg was initiated by RTW for all patients; however, prednisone was initiated by other neurologists in 7 patients.
IVIg was given monthly at 1 g/kg. Select patients underwent IVIg infusions every 3 weeks if seizures recurred or escalated by the week of their next infusion. IVIg was not given at intervals of less than 3 weeks. Repeated infusions were offered in patients who responded and relapsed. Prednisone initiated by RTW was prescribed at 2 mg/kg/day (maximum 60 mg/day) for 2 weeks followed by a 6-8 week taper. Prednisone initiated by other neurologists was prescribed at 1-2 mg/kg/day (maximum 60 mg/ day) for 2-4 weeks followed by a 4-6 week taper. Repeated courses of prednisone were offered in patients who responded and relapsed. If patients did not respond to one treatment option, the other treatment option was offered.
Data was analyzed retrospectively and included sex, etiology of the epilepsy (lesional, unknown, genetic), age at time of first seizure, number of seizure types, baseline seizure frequency prior to treatment, number of AEDS tried, age at time of first IVIg or prednisone treatment, follow up time from first IVIg or prednisone treatment, best seizure response, time of first perceived seizure reduction, time of best seizure response, adverse effects, ability to reduce or discontinue AED's, response to subsequent courses of treatment, and EEG at time of best seizure response.
Because seizure frequency can vary in a given month, the baseline seizure frequency was defined as the average monthly seizure frequency that was sustained for a minimum period of 2 months prior to treatment and that was not due to an exacerbation from a transient condition. Responders to therapy were defined as having seizure reductions of at least 50% that persisted for a minimum period of 2 months. Best seizure response was defined as the maximum percentage of seizure reduction from baseline seizure frequency. Seizure frequencies were obtained from parental reports. These reports were compared to the seizure frequency reported by medical personnel in other clinical settings. Patients were excluded if there were significant inconsistencies in seizure reporting. A reduction in the spike frequency was defined as a 50% or greater reduction in spiking during comparable awakesleep states on EEG before and after therapy.
Median values were used as a representation of the centre value because of the non-normal distribution of the data. The MannWhitney U test was therefore used to analyze the differences between the cohorts. Correlation between variables was determined by exploratory analysis of the scatterplot of the data and then by linear regression analysis.
Results
Fifty-one patients met the inclusion criteria: 26 patients received IVIg treatment, and 25 patients received high dose prednisone. The age at the time of the treatment initiation ranged from 2 to 13 years in the IVIg group, and from 18 months to 10 years in the prednisone group. One patient from the IVIg cohort was excluded due to unreliable reporting and non-compliance with medications.
Tables 1a and 1b show the characteristics of the patients of both cohorts and include the epilepsy etiology, type of epilepsy, duration of epilepsy until time of treatment with IVIg or high dose prednisone, and percent seizure reduction with treatment. Table 2 summarizes and compares the IVIg and prednisone cohorts. The mean age of seizure onset was 25.9 months in the IVIg group and 19.5 months in the steroid group. All children had tried multiple AEDs prior to the treatment initiation. Focal epilepsies accounted for 38.5% of the IVIg cohort and 8.0% of the prednisone cohort. The epilepsy etiologies were more evenly distributed between the cohorts. The mean duration of epilepsy prior to treatment was 1.3 fold higher in the IVIg cohort (60.3 months vs. 45.6 months). In total, 10 patients from the prednisone cohort subsequently underwent IVIg treatment due to poor response while only 1 patient from the IVIg was then treated with prednisone. For most patients who underwent treatment with prednisone before IVIg, there was an adequate wash out periods of greater than 1 year. Only patient #7 in the IVIg group (patient #10 in the prednisone cohort) received prednisone during the initial 6 months of IVIg because this patient's seizures had escalated and more aggressive therapy was required. The combination or prednisone and IVIg did not have any significant impact on this patient's seizures.
Within the IVIg cohort, 22 patients (84.6%) responded with a mean seizure reduction of 65.4% and a range of 0-100%. The mean seizure reduction among responders was 77.3%. The earliest time of first noted seizure reduction was 2 weeks after the first infusion with a mean time of 5.9 weeks. The mean time until best seizure reduction was 9.8 weeks after the first infusion (after the third infusion). Initial response followed by a sustained seizure relapse unaffected by at least 2 further IVIg infusions (honeymoon effect) was seen in 4 patients (2 unknown, 1 genetic, and 1 lesional). The majority of the genetic, unknown, and lesional epilepsies responded to IVIg. Of note, all children with lesional epilepsies had significant seizure reductions: all children with cortical dysplasia became seizure free and all children with lissencephaly had a 50% seizure reduction that was sustained. Epilepsy etiology, type, and duration prior to treatment did not appear to correlate with response. In total, 9 children in the IVIg cohort did not require any change to their AEDs, and AEDs were reduced in 8 children. Nine of the IVIg responders had reduced seizures that were sustained for periods ranging from 1-16 months (mean 6.6 months) after IVIg was discontinued. Patient #6 who had a response with the first course of IVIg relapsed and received an additional round of IVIg; however, with the second round of infusions, the first noted response occurred 24 weeks after monthly IVIg was restarted and the best response occurred at 28 weeks as opposed to 12 weeks and 20 weeks, respectively, with the first course of IVIg. Patient #1 had a recurrent seizure that was provoked by illness but no recurrent spontaneous seizures. The parents of all responders noted improved alertness, behaviour, and learning abilities.
In the prednisone cohort, 6 patients (24%) responded. There appeared to be an all or none type of response with a range of 70-100% seizure reduction with 5 achieving seizure freedom (mean seizure reduction of 95.0% among responders). Patients 6 and 19 remained seizure free for over 1 year after prednisone. Despite the Legend: KD = Ketogenic Diet; MAD = Modified Atkins Diet; Pred = High dosage prednisone; del = deletion; mut = mutation; N/A = not applicable; À = no data. Patient #11 was excluded from the study due to inconsistent seizure reporting. Patient #6 underwent 2 rounds of IVIG infusions due to relapsed seizures. The data in parentheses denotes the time of first noted response, best response, and the duration of best response from the time of the first IVIG infusion with the second round of infusions. In comparing the cohorts, the percent of seizure reduction for IVIg patients (mean rank = 32.13) was statistically significantly higher than for the prednisone patients (mean rank = 19.62), pvalue = 0.001. Regarding the number of responders, there was a statistically significant difference between the cohorts in proportions of 60.6%, p-value < 0.0001.
No correlation was found between the percent of seizure reduction and duration of the epilepsy; moreover, no clear difference in duration of epilepsy prior to treatment was found between responders and non-responders. Patients who responded to prednisone were older at time of first seizure (median age 25.0 months; mean age 29.00 months; 95% CI [2.62, 55.38]). Patients who responded to IVIg were younger at time of first seizure (median age 12.5 months; mean age 25.27 months; 95% CI [11.86, 38 .68]). For both cohorts, the confidence intervals for mean values were large because of small sample sizes.
Although follow-up EEG's were not consistently performed in all patients in the IVIg cohort, 8 responders had reduced spike frequencies with 3 of them having normalization of their EEG's. The EEG remained unchanged in 3 IVIg responders. Similarly, 4 prednisone responders had reduced spike frequencies with only 1 of these patients having normalization of the EEG. The EEG did not change in the remaining 2 prednisone responders.
Sixteen (64.0%) of the prednisone treated children had significant adverse effects consisting mainly of cushingoid features, aggressive behaviour, irritability and hyperactivity. The majority of the parents of these patients, including the responders, refused repeated prednisone treatment. By contrast, only 2 patients (8.3%) in the IVIg cohort had adverse effects consisting of migraines. All parents of the IVIg responders had no objections to continuing or resuming IVIg, and the parents of 12 patients had expressed a preference for IVIg over AEDs.
Discussion
The typical course of intractable epilepsy is an escalation of seizures refractory to titration of AEDs. For our patients, the ultimate hope had always been to achieve seizure freedom; however, the decision to use IVIg or prednisone was to reduce seizures as much as possible, avoid further AED escalation, reduce AEDs, and improve quality of life. Indeed, in some epilepsies, therapy is often targeted to certain seizure types while allowing minor and less harmful seizures to continue. A re-definition of goals of this kind is often required in intractable epilepsy as it is more realistic and acceptable to parents. With these goals in mind, IVIg had been more successful in achieving them in our patient population as compared to prednisone.
Our findings are similar to what has been reported in the literature. Bello-Espinosa et al. reported a response to IVIg in 81% of children [9] . It remained unclear however whether IVIg treatment could ever be discontinued as all patients in the study continued IVIg therapy; moreover, there were no specific details regarding response with specific etiologies, timing of response, and impact of the duration of epilepsy. In comparison to their study, their Indicates the patients whose prednisone was initiated by RTW at 2 mg/kg/day as described in the Methods.
reported response rate was comparable to our response rate of 84.6%. In our IVIg cohort, moreover, IVIg infusions were discontinued in 7 patients with subsequent preservation of seizure reduction. The lesional epilepsies in our study showed a particularly strong response to IVIg treatment as all eight patients responded.
A variety of protocols using corticosteroids in treating epilepsy have been reported. They ranged from pulse methylprednisolone (15-30 mg/kg/day for 3-4 days given monthly for 3-4 months) [10] , pulse methylprednisolone (15-30 mg/kg/day for 3-4 days) followed by a prednisone taper [11, 12] , high dosage prednisone (1-2 mg/kg/day) for 1-2 months [13] , and ACTH (10-30 iu/day) given for 10-57 days [14] . The studies using each of these protocols all reported effectiveness with responder rates ranging widely from 35%-86%. There did not appear to be a specific protocol, choice and dosing of corticosteroid, or duration of therapy that has been shown to be superior in treating children with intractable epilepsy. Responder rates of over 70% were reported in the studies using oral prednisone [13] . With our prednisone treatment protocol, our patients were taking dosages of >1 mg/kg/day for approximately 6 weeks. Our protocol was therefore deemed consistent with the literature.
Almaabdi et al. reported that intravenous methylprednisolone is a useful and well-tolerated option in intractable epilepsy [10] . Only 6 (35%) children in their study became seizure free with 3 relapsing. An additional 4 patients (24%) children were found to have improved seizure control 6 months post treatment. Our response rate was similar with 6 (24.0%) and 4 relapsing; however, no improved seizure control post treatment was observed in our cohort over a mean follow-up time of 32.3 months. In addition, there appeared to be an all or none response in our cohort as the majority of patients had either complete seizure cessation or no response. We also observed a much higher incidence of adverse effects. Other studies reported higher responses of >40% [12] and >70% [13] . Our lower response was likely due to the greater diversity of etiologies included in our cohort and our more stringent definition of response; moreover, treatment with prednisone occurred earlier in the course of the patient's epilepsy and not at its nadir when terminal remission can occur [10, 15] .
Although our data is encouraging, our study was limited because it was retrospective and non-blinded. There were therefore several avenues for potential bias. A major drawback was the subjective reporting of seizure reduction and improvement of co-morbidities by parents. It was difficulty to objectively measure seizure reduction, and thorough neuropsychological testing was not consistent and difficult to access in a timely fashion. In addition, it was only in recent years that there was greater accessibility to IVIg at our centre. This difference in accessibility may have led to bias in offering prednisone during the earlier years and could have accounted for the greater mean duration of epilepsy in the IVIg cohort. By contrast, the much higher number of IVIG responders became very apparent during the study's time frame. This information along with the reported higher adverse effects with prednisone were disclosed to parents prior to treatment and may have added to further bias. Regarding the study results, the prednisone cohort in our study had a predominance of generalized epilepsy which may have skewed the findings despite the more equal distribution of the epilepsy etiologies between the cohorts. Moreover, our findings that responders to IVIg were younger at time of epilepsy onset as compared to prednisone responders is of unclear significance given the large CI and small sample size. Although bias may also have contributed to this finding, it is still intriguing and worth evaluating in a future study.
To address and circumvent these shortcomings, it would be ideal to conduct a prospective, randomized, placebo controlled, double blind study for both IVIg and corticosteroid with specified age groups, duration of epilepsy, and epilepsy etiology. Such a study should also include a more rigorous data collection protocol that would include consistent and scheduled neuropsychological assessments and prolonged video-EEG monitoring. In addition, a corticosteroid protocol with far fewer adverse effects than oral prednisone should be used such that adverse effects are not a deterrent. Indeed, it is the authors' intention to conduct this type of study in the near future.
Currently, the precise mechanism of action of IVIg and prednisone in the treatment of epilepsy remains unclear. Modulation of neuroinflammation is a suspected mechanism of actions for both as neuroinflammation and immune mediated changes to the neural substrate are thought to contribute to intractability [2, 6] . Recently, microglial activation and neuroinflammation were found to accompany focal dysplasia and temporal lobe epilepsy [3, 4, 22] . The extent of microglial activation is thought to correlate with seizure frequency pointing to an immune system dysregulation during the epileptogenesis leading to seizure propagation. Immune-mediated antibodies and cytokines appeared disproportionately in epileptic patients [16, 17] , and neuronal antibodies have been found in 9.5% of new onset paediatric epilepsy [21] . The authors further report that the antibodies did not persist and can occur transiently either early or late in the course of epilepsy. These inflammatory processes are thought to act as inducers of neuroplastic changes that subsequently lead to decreased seizure threshold [18, 19] . Despite the wide range of reported immune abnormalities in epilepsy, it is unclear if these changes are a causal immune response or a reactive immune response [20] .
Although both IVIg and corticosteroids have immunomodulatory properties, the findings of this study have implications in understanding how IVIg and prednisone influence epileptogenesis. One difference noted between prednisone and IVIg was the faster mean time of response of 2.7 weeks seen with prednisone as compared to the mean time of first noted response of 5.9 weeks and a mean time of best response of 9.8 weeks with IVIg. Although the reason for this difference is unclear, it does suggest that prednisone and IVIg must employ difference mechanisms of action in affecting seizures. Prednisone's suspected effect on membrane stabilization and neuronal excitability that may be more immediate but temporary. Its longer lasting effects may be due to its influence as on gene transcription which also appear to be temporary given the higher relapses seen in this study and reported in the literature. The discrepant response in patients with the same epileptic etiology and syndrome like Doose Syndrome (patients 7, 18, 19) and Childhood Absence Epilepsy (patients 5 and 6) is puzzling. By contrast, these discrepant responses were not seen with IVIg, and its delayed response may reflect the time taken to reverse the suspected changes to the neural substrate that led to intractability. Because the response to IVIg seemed independent of epilepsy etiology and epilepsy duration prior to IVIg, it is likely that there is a final common pathway leading to intractability. The high number of responders and the sustainability of the best response after IVIg treatment imply that this pathway is reversible and immune mediated but distinct from the action of prednisone and conventional AEDs.
We propose that neuroinflammation and immune mediated changes seen in epilepsy are likely the by-product of continuing seizures and ongoing epileptic activity promoting further seizures and intractability. The effect of IVIg seen in our cohort may not necessarily cure the epilepsy but the effect of IVIg may make a patient's epilepsy more amenable to AED therapy. Indeed, if it is true that epileptogenesis is a continuous, evolving process [23] where the immune system plays a role in the development of intractability and co-morbidities, then perhaps treatment with IVIg should be considered early in the course of epilepsy and not after intractability has persisted. Further studies are of course needed to support this supposition. At the very least, however, our study does suggest that IVIg can be a well-tolerated and useful AED sparing agent.
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